A landmark 2026 meta-analysis confirms 54 percent of Type 2 diabetes patients suffer from fatty pancreas disease (FPD). The study reviewed 12 studies involving over 6,300 participants, identifying FPD as a major metabolic burden.
FPD impairs both endocrine and exocrine pancreatic function and affects one in five people globally. Researchers emphasize its role as a key contributor to Type 2 diabetes development.
While findings support improved clinical awareness and risk stratification, routine FPD screening remains unsupported by current evidence. Experts urgently call for prevention strategies and metabolic monitoring protocols.